News

Kidney failure patients on dialysis derive long-term benefit from the minimally invasive placement of a stent that improves the function of dialysis access grafts, according to 12-month clinical...

Zilver Vena

Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the treatment of...

The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD...

Reva Medical Inc. announced that it has initiated patient enrollment with its ReZolve2 bioresorbable sirolimus-eluting coronary scaffold.

Medtronic Resolute Drug Eluting Stent Dual Antiplatelet Therapy Clinical

Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic Inc. as participants in one of several clinical studies and...

NeuroVive announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center clinical trial (CIRCUS trial) assessing CicloMulsion (a special formulation of...

March 26, 2013 — A multicenter analysis, led by Weill Cornell Medical College and published in the Journal of Clinical Gastroenterology, shows the use of temporary "fully covered...

Cordis Corp. announced it has completed the acquisition of Flexible Stenting Solutions Inc., whose technology provides Cordis with the opportunity to evolve the S.M.A.R.T. stent platform to...

Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) study at Middelheim...

Absorb Bioresorbable Vascular Scaffold Clinical Trial Acc 2013

Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial...

OrbusNeich announced that OrbusNeich Medical GmbH has commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corp. and its distribution affiliates in those...

Medtronic Resolute Integrity Stent FDA Approval 34, 38 mm

The U.S. Food and Drug Administration (FDA) has approved the 34 and 38 mm lengths of the Medtronic Resolute Integrity drug-eluting stent in diameters of 3, 3.5 and 4 mm with an indication for...

Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES...

Biosensors BioMatrix

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloon catheters....

BioSensors International BioFreedom Drug Coated Stent CE mark

Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS), BioFreedom.

Bioresorbable Stent GlobalData Peripheral Artery Disease

Coronary artery disease and peripheral artery disease are global health issues that affect millions of lives each year, and bioabsorbable stents are due to become the next step in treatment once...

The American College of Cardiology (ACC) has released the late-breaking clinical trials that will be highlighted as the cutting edge of cardiology at the ACC.13 annual meeting March 9-11 in San...

Biotronik BIOFLEX-I IDE Clinical Trial Puslar-18 Peripheral Artery Disease

Biotronik announced the first U.S. implant of their Pulsar-18 self expanding stent in the BIOFLEX-I IDE clinical trial. Carlos Mena of Yale University Medical Center performed the procedure.

Abbott Absorb bioresorbable stent

Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of...

Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical study involving BioFreedom, a polymer-free drug-coated stent (DCS) from Biosensors.